Pioglitazone Induced Reversible Pancytopenia


Karakurt F., Kargili A., KASAPOĞLU B.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, vol.118, no.2, pp.96-97, 2010 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 118 Issue: 2
  • Publication Date: 2010
  • Doi Number: 10.1055/s-0029-1234065
  • Journal Name: EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.96-97
  • Keywords: pioglitazone, diabetes mellitus type 2, pancytopenia, THIAZOLIDINEDIONES
  • Lokman Hekim University Affiliated: No

Abstract

Pioglitazone is used to improve insulin sensitivity in type 2 diabetes. This group of drugs is usually well tolerated; however, their use may be associated with several adverse effects including edema, weight gain, macular edema and heart failure. Herein we report a patient who developed pancytopenia on the 7th day of oral pioglitazone treatment for the control of diabetes mellitus and fully recovered 6 days after the cessation of this drug. To the best of our knowledge this is the first reported case of pancytopenia induced by pioglitazone therapy.